MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Trading 07-02 09:57:00 EDT

1.49

+0.06

+4.20%

High1.49	Low1.45	Vol42.34K
Open1.45	D1 Closing1.43	Amplitude2.81%
Mkt Cap90.40M	Tradable Cap82.88M	Total Shares60.67M
T/O62.05K	T/O Rate0.08%	Tradable Shares55.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.49,"timestamp":1783000594351,"preClose":1.43,"halted":0,"volume":42337,"delay":0,"changeRate":0.041958041958041994,"floatShares":55623100,"shares":60671491,"eps":-0.665719,"marketStatus":"Trading","change":0.06,"latestTime":"07-02 09:57:00 EDT","open":1.4498,"high":1.49,"low":1.4498,"amount":62048.810841,"amplitude":0.028112,"askPrice":1.49,"askSize":300,"bidPrice":1.47,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":-0.665719,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783022400000},"marketStatusCode":2,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.4416,"preClose":1.43,"latestTime":"08:59 EDT","volume":226,"amount":325.8016,"timestamp":1782997162540,"change":0.0116,"changeRate":0.008112,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.43,"preClose":1.43,"latestTime":"19:38 EDT","volume":2837,"amount":4029.6133,"timestamp":1782949085774,"change":0,"changeRate":0,"amplitude":0.013986},"volumeRatio":1.228204},"requestUrl":"/m/hq/s/MAIA/wiki","defaultTab":"wiki","newsList":[{"id":"2646605870","title":"Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646605870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646605870?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA5MLKGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870966","title":"MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870966?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":"Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June  25, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/MAIA-Biotechnology-Completes-International-Enrollment-in-Part-C-of-Phase-2-THIO-101-Expansion-Trial-in-Third-Line-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","BK4139","LU0053666078.USD","LU0210528500.USD","L","ORR","BK4588","BK4107","LU2487616109.SGD","MAIA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644810085","title":"Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644810085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644810085?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785888,"startTime":"0","endTime":"0","summary":"Maia Biotechnology opened enrollment at Emory University’s Winship Cancer Institute for its Phase 2 THIO-101 expansion trial in third-line NSCLC.The study evaluates ateganosine, a telomere-targeting agent, followed by cemiplimab in patients resistant to checkpoint inhibitors and chemotherapy.Early results from Parts A and B have already been presented, showing encouraging clinical benefit in some patients.The U.S. expansion adds a third domestic site, supporting broader recruitment for a setting with no FDA-approved third-line options.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbNrbBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4585","BK4139","SG9999014039.USD","IE00B3QW5Z07.USD","MAIA","IE00BGHQF748.EUR","BK4112","IE00BN0W2V16.EUR","LU0314104364.USD","NDAQ","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808302","title":"Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808302?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:30","pubTimestamp":1781785800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUABM17DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167022508","title":"Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1167022508","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167022508?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:20","pubTimestamp":1781191233,"startTime":"0","endTime":"0","summary":"Clinical-stage cancer immunotherapy company Compugen Ltd. announced on Thursday that it will present the latest progress from its MAIA-ovarian trial in a poster presentation at the 2026 European...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442946","title":"Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442946","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442946?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:20","pubTimestamp":1781097631,"startTime":"0","endTime":"0","summary":"Maia Biotechnology opened enrollment at a second US site for its Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer.No new results were presented; additional expansion data are expected in future interim updates to support a potential FDA accelerated approval filing.The study evaluates ateganosine in patients who failed checkpoint inhibitors and chemotherapy, aiming to show clinically meaningful benefit without detailing metrics.Maia is also screening patients for a pivotal Phase 3 overall-survival study comparing ateganosine sequenced with a CPI versus investigator’s-choice chemotherapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6MN2LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642542915","title":"Maia Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 Thio-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642542915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642542915?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA2X2ZSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209429","title":"MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209429?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":"Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/MAIA-Biotechnology-Activates-and-Opens-Enrollment-at-Second-U-S-Clinical-Site-for-International-Phase-2-THIO-101-Expansion-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2487616109.SGD","L","BK4107","EMA","LU0053666078.USD","MAIA","LU0210528500.USD","BK4081","ORR","BK4585","CPI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640316357","title":"MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640316357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640316357?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:50","pubTimestamp":1780581010,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-29-patients-dosed-in-phase-3-thio-104-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-29-patients-dosed-in-phase-3-thio-104-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640687421","title":"MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640687421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640687421?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:45","pubTimestamp":1780580714,"startTime":"0","endTime":"0","summary":"Maia Biotechnology reported strong enrollment momentum in THIO-104, a pivotal Phase 3 trial of ateganosine in third-line advanced non-small cell lung cancer.No new efficacy results were presented; the update focused on trial progress and timing for future readouts.29 patients have been dosed across 34 active sites in six countries, with a target of up to 100 patients by year-end.An interim analysis is expected in 2027 once survival follow-up matures, setting the next key catalyst for the program.Ateganosine holds FDA Fast Track status, supporting a potentially accelerated development and regulatory path if Phase 3 data are positive.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL9HYVqc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","SG9999014005.SGD","BK4139","MAIA","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640168788","title":"Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640168788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640168788?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:45","pubTimestamp":1780580700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA4MW6GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640900487","title":"MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640900487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640900487?lang=en_us&edition=fundamental","pubTime":"2026-06-03 22:23","pubTimestamp":1780496602,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of the phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer.The firm said it obtained clearance of its updated investigational new drug application highlighting improved manufacturing capabilities, including new manufacturers and formulation.In addition to the US, the THIO-101 study is ongoing at 44 clinical sites in six countries, it added.The additional data from the expansion studies may further support a filing for an accelerated approval, MAIA said.Shares were up over 4% in morning trading.Price: 1.41, Change: +0.06, Percent Change: +4.44","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4139","LABU","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640900874","title":"MAIA Biotechnology receives FDA clearance for amendment to IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2640900874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640900874?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:55","pubTimestamp":1780494955,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that the U.S. Food and Drug Administration has cleared an amendment to update its investigational new drug appl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-receives-fda-clearance-for-amendment-to-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-receives-fda-clearance-for-amendment-to-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4588","LABU","IND","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640690716","title":"Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2640690716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640690716?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:45","pubTimestamp":1780494300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8ZYMYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640946299","title":"MAIA Biotechnology announces open market purchases by CEO, director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640946299","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640946299?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:52","pubTimestamp":1780408340,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan Smith, Ph.D. have increased their ownership positio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-open-market-purchases-by-ceo-director-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-open-market-purchases-by-ceo-director-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640946283","title":"Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640946283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640946283?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:50","pubTimestamp":1780408234,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on West Pharmaceutical Services (WST) and MAIA Biotechn...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-west-pharmaceutical-services-wst-and-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-west-pharmaceutical-services-wst-and-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","IE00BFXG0V08.USD","BK4588","MAIA","LU0128526141.USD","HCSG","WST","BK4504","LU0345774391.USD","IE00BYQQ9H92.USD","LU0345774631.USD","BK4567","BK4121","LU0106261612.USD","BK4581","LABU","LU0012050646.USD","IE00B64QTZ34.USD","BK4585","LU0029874061.USD","BK4139","BK4137","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640466159","title":"MAIA says directors, officers hold 20.46% beneficial stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2640466159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640466159?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:48","pubTimestamp":1780408139,"startTime":"0","endTime":"0","summary":"Maia Biotechnology disclosed open-market stock purchases by founder-CEO Vlad Vitoc and director Stan V. Smith.Vitoc bought 72,700 shares on June 6 at an average price of $1.39.Smith bought 75,000 shares on June 6 at an average price of $1.34.Directors and officers collectively hold a 20.46% stake.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL44LYW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640563946","title":"Maia Biotechnology Announces Open Market Purchases by CEO and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640563946","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640563946?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:45","pubTimestamp":1780407900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA2RVKRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943009","title":"Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943009","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943009?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:02","pubTimestamp":1780405371,"startTime":"0","endTime":"0","summary":"Maia Biotechnology CEO Vlad Vitoc bought 72,700 common shares at a weighted average price of $1.39.Form 4 also reports 210,100 common shares held indirectly through his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7j7kl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943026","title":"Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943026","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943026?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:02","pubTimestamp":1780405329,"startTime":"0","endTime":"0","summary":"Maia Biotechnology director Stan V. Smith reported a purchase of 75,000 common shares at a weighted average price of USD 1.34.Beneficial ownership rose to 1,519,178 shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLbVvkMq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.MAIABiotech.com","stockEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.1},{"period":"3month","weight":0.0752},{"period":"6month","weight":-0.1063},{"period":"1year","weight":-0.2552},{"period":"ytd","weight":-0.0654}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.026788},{"month":4,"riseRate":0.5,"avgChangeRate":0.130553},{"month":5,"riseRate":0.75,"avgChangeRate":0.111873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.089611},{"month":7,"riseRate":0.25,"avgChangeRate":-0.045297},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}